High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis

Arthritis and Rheumatism

Volumn 58, Issue 1, 2008, Pages 284-291

  Allanore, Y ^a,c   Borderie, D ^a   Avouac, J ^a   Zerkak, D ^a   Meune, C ^a   Hachulla, E ^b   Mouthon, L ^a   Guillevin, L ^a   Meyer, O ^a   Ekindjian, O G ^a   Weber, S ^a   Kahan, A ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIV LILLE   (France)

^c Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARBON MONOXIDE;

ADULT; AGED; ARTICLE; CAPILLARY; CLINICAL EVALUATION; COHORT ANALYSIS; FEMALE; HUMAN; LUNG ALVEOLUS CARBON DIOXIDE TENSION; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RISK ASSESSMENT; SYSTEMIC SCLEROSIS;

ADULT; AGED; BIOLOGICAL MARKERS; CAPILLARIES; CARBON MONOXIDE; COMORBIDITY; DIFFUSION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 38149040974     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23187     Document Type: Article

References (28)

1. Distler O, Pignone A. Pulmonary arterial hypertension and rheumatic diseases: from diagnosis to treatment. Rheumatology (Oxford) 2006;45 (Suppl 4):iv22-5.
2. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
3. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001;40:453-9.
4. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
5. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003;124:2098-104.
6. Allanore Y, Borderie D, Meune C, Cabanes L, Weber S, Ekindjian OG, et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003;48:3503-8.
7. Mukerjee D, Holmes AM, Nair D, Ayrton P, Black CM, Coghlan JG. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003;97:1230-6.
8. Williams MH, Akram R, Smith CJ, Das C, Smee J, Nair D, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006;27:1485-94.
9. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006;92:843-9.
10. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006;98:525-9.
11. Hargett CW, Tapson VF. Brain natriuretic peptide: diagnostic and therapeutic implications in pulmonary arterial hypertension. Semin Respir Crit Care Med 2005;26:385-93.
12. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
13. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002;81:154-67.
14. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al, the Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004;25:2243-78.
15. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003;29:255-73.
16. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CI, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2-10.
17. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002;81:139-53.
18. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-50.
19. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40.
20. Gan CT, McCann MG, Marcus JT, van Wolferen SA, Twisk JW, Boonstra A, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J 2006;28:1190-4.
21. Blyth KG Groenning BA, Mark PB, Martin TN, Foster JE, Steedman T, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 2007;29:737-44.
22. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001;104:2797-802.
23. Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 2006;45 (Suppl 4):iv14-7.
24. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
25. Distler O, Behrens F, Huscher D, Foeldvari I, Zink A, Nash P, et al. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Rheumatology (Oxford) 2006;45:1455-7.
26. Matucci-Cerinic M, D'Angelo S, Denton CP, Vlachoyiannopoulos P, Silver R. Assessment of lung involvement. Clin Exp Rheumatol 2003;21:S19-23.
27. Collins N, Bastian B, Quiqueree L, Jones C, Morgan R, Reeves G. Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I). Eur J Echocardiogr 2006;7:439-46.
28. Nikolaou K, Schoenberg SO, Attenberger U, Scheidler J, Dietrich O, Kuehn B, et al. Pulmonary arterial hypertension: diagnosis with fast perfusion MR imaging and high-spatial-resolution MR angiography: preliminary experience. Radiology 2005;236:694-703.